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The effects on tubulin dynamics of paclitaxel, ortataxel and two recently developed taxol derivatives 
bearing a five-membered heterocyclic ring fused at the 1,14 position were analysed by means of 
molecular dynamic simulations and MMPBSA approach. Tubulin polymerization kinetics and 10 
microtubule morphology assays were also conducted, providing support to computational results. In 
particular, it has been shown that the two recently developed 1,14-heterofused taxanes IDN5839 and 
IDN5798 are able to speed up the in vitro tubulin assembly by promoting the nucleation phase and to 
affect microtubule network in cell earlier than paclitaxel. 
Introduction 15 
The microtubule-targeted drug paclitaxel (Taxol®, 1, Figure 1) is 
widely used in clinical practice for cancer therapy.1 
 
Figure 1. Paclitaxel (1) and ortataxel (2) 
 Nevertheless, the research of analogues endowed by a more 20 
favourable pharmacological profile, in terms of selectivity and 
tolerability, is still necessary.  
 Structure-activity studies of several research groups leaded to 
the observation that changes to the “southern hemisphere”, 
comprising the C14 and C1 to C5 positions, exert a major effect 25 
on paclitaxel activity.2,3 As a demonstration, the potent anticancer 
taxoid ortataxel (2, Figure 1), was prepared starting from 14β-
hydroxyl-10-deacetylbaccatin III 1,14-carbonate, a semi-synthetic 
intermediate obtained from the naturally abundant 10-deacetyl 
baccatin III.4 Ortataxel displays improved pharmacological 30 
properties, such as a remarkably higher oral bioavailability than 
paclitaxel and entered clinical trials where it showed a strong 
activity in Phase II studies on heavily pre-treated metastatic 
breast and non-small cell lung cancer.5 To further improve the 
pharmacological properties of ortataxel, new C14 isosters were 35 
recently prepared by our research group.6 
 The development of highly active derivatives takes 
unquestionable advantages by the knowledge of bioactive 
conformations (Figure 2). 
 40 
Figure 2. Proposed bioactive conformations for paclitaxel  
 The binding conformation of taxol and its derivatives has been 
the object of several investigations. A bioactive non-polar 
conformation Ia, showing the clustering of the C2 benzoate and 
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the C3' benzamido group, was proposed by single conformation 
NMR studies in apolar solvents,7 while analogous NMR 
investigations conducted in polar solvents suggested the 
hydrophobically collapsed “polar” conformation Ib.8 However, 
most of the constrained taxol mimic designed upon both the non-5 
polar and the polar conformations resulted less potent than taxol 
itself.9 The T-taxol conformation Ic, supported by theoretical 
models derived from electron crystallographic density studies as 
well as by several experimental observations based on 
constrained taxol analogues,10 was finally proposed as the 10 
bioactive conformation.11 
 Concerning taxol derivatives, the binding modes of IDN5390 
(a seco-derivative of taxol) and epothilone A to type I and III 
isoforms of β-tubulin were investigated by means of restrained 
molecular dynamic (MD) simulations, providing structural 15 
insights about the recognition mode of those antimitotics.12  
 MD simulations were also conducted on a microtubule 
fragment model (two parallel protofilaments formed by two α and 
one β subunit) both in presence and absence of paclitaxel,13 
revealing through a root-mean-square-fluctuation analysis that 20 
paclitaxel induces changes in the dynamics of the loops 
surrounding the taxol binding site. The authors suggested that 
such changes, by affecting the protofilament flexibility, favour 
the interactions between adjacent protofilaments. Variations in 
the dynamics at the β-α interface were also observed, but no 25 
details were given on the process thermodynamics and, 
consequently, on the eventual stabilization of the head-to-tail 
interaction between tubulin dimers in a single protofilament. 
 In the present work we investigated the binding mode and the 
interaction energies for tubulin complexes of ortataxel (2) and the 30 
recently developed 1,14-heterofused taxanes IDN5839 (3) and 
IDN5798 (4) represented in Figure 3. 
 
Figure 3. 1,14-Heterofused taxanes analysed in the present study. 
 Paclitaxel was also included in the study for comparison and to 35 
test the reliability of our computational approach. Potential 
binding geometries for 1-4 were generated and then evaluated by 
MD simulations and molecular mechanics/Poisson Boltzmann 
surface area (MM-PBSA) calculations.  
 Moreover, the long range effects of taxanes binding on 40 
residues at the 1α-2β interface were evaluated on 1β,1α-2β,2α 
tubulin tetramers by MD and MM-PBSA calculations, a method 
that proved to be successful in designing peptides interfering with 
the dimer-dimer interaction of tubulin,14 and per-residue free 
energy decomposition analysis. 45 
 Finally, experiments on tubulin polymerization kinetics and on 
microtubule morphology were also conduced, and the comparison 
between theoretical and experimental findings revealed 
significant differences in the biochemical behaviour of the 
investigated 1,14-heterofused taxanes. 50 
Results and Discussion 
Computational Study. 
 Binding mode and binding energy analysis. Although the 
structure of the α,β-tubulin dimer complexed with 1 has been 
determined by electron crystallography at 3.5 Å,15 it lacks the 55 
necessary resolution to define the binding conformation of 1 
itself. Despite this, the T-taxol bioactive conformation has been 
widely supported by binding studies with highly active 
constrained analogues10a,d and REDOR NMR experiments.11c To 
our knowledge, no information are available upon the bioactive 60 
conformation of 1,14-heterofused taxanes 2-4, and the 
assumption of an analogue binding mode with 1 might be 
dangerous due to the differences at the 1,14 positions and in the 
side-chain, which bears a t-butylcarbamate and a sec-butyl 
instead of benzamide and phenyl groups.  65 
 
Figure 4. Superposed Lowest energy conformations obtained for the 
unbounded taxanes 1-4 by low-mode MD conformational search with the 
MMFF94x force field and Born solvation. 1 (green), 2 (yellow), 3 (cyan), 
4 (magenta). Lowest energy conformations obtained for the unbounded 70 
taxanes by low-mode MD conformational search with the MMFF94x 
force field and Born solvation.  
 A conformational search of unbounded compounds 2-4 was 
then performed using the low mode MD algorithm and the 
MMFF94x force field with Born solvation for water, 75 
implemented in the MOE software.16 Paclitaxel 1 was also 
included and the obtained conformation showed for this 
compound a geometry highly consistent with the REDOR-NMR 
supported T-taxol conformation.11c Compounds 2-4 also provided 
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comparable conformations, as shown by Figure 4 where the 
lowest energy conformations are superposed. Due to the 
structural differences in the side-chain and in the 1,14 region, the 
obtained conformation for 2-4 will be hereafter referred as 
pseudo-T-taxol. It should be noted that, in the superposed 5 
geometries represented in Figure 4, the side-chain tert-
butoxycarbonyl groups of compounds 3 and 4 and the side-chain 
benzoyl group of 1 are closely matched, while compound 2 
shows an higher deviation (computed r.m.s.d. between the amidic 
carbonyl groups of 2, 3 and 4 compared to 1 are 0.14, 0.11, 0.12 10 
Å, respectively). Although, by considering all the common heavy 
atoms in r.m.s.d. calculation between compounds 1 and 2-4, the 
closest match with 1 is observed for compound 2 (r.m.s.d. = 2.83 
Å) followed by 4 and 3 (r.m.s.d. = 3.79 and 3.85Å, respectively). 
 In order to evaluate the stability of the obtained conformations 15 
within the binding environment, complexes were realized by 
manually docking said conformations of 1-4 into the β subunit of 
a tubulin dimer model derived from the 1JFF crystal structure.15 
The complexes were processed by MD simulations in explicit 
water and, after a careful equilibration, a 2 ns production run was 20 
performed, a length considered adequate in similar and recently 
published studies.14  
 In order to verify the possibility of alternative binding 
conformations, different starting complexes were also generated 
by automated docking, using two different protocols previously 25 
optimized in order to reproduce at best the experimentally 
determined binding conformation of 1 (see Experimental for 
details). For each compound, the top five poses of both protocols 
were used for generating complexes which were subjected to the 
MD procedure described above. All trajectories were then 30 
analysed by MM-PBSA, a reliable method to discriminate 
different binding conformation by computing free energies of 
binding on a statistically relevant thermodynamic ensemble.17 In 
order to select a proper binding conformation, the MM-PBSA 
derived complex absolute stabilities and ligand binding energies 35 
were both evaluated. Table 1 reports the binding energies 
obtained for the lowest energy pose (see Table S1, Supporting 
Information, for full results), together with geometrical 
parameters selected to provide a common term of comparison 
between 1 and the 1,14-heterofused taxanes 2-4 (Figure 5). 40 
 
Figure 5. Distances d1 (C1'=O∙∙∙C14), d2 (C14∙∙∙O=CNH), d3 
(HNC=O∙∙∙O=C1'), d4 (C11-OCOCH3∙∙∙C3’); torsion angles φ1 and φ 2 
(O-C2-C3'-N and O-C2-C3'-C, accordingly to reference 11a), and 
dihedral angles φ 3 and φ 4 (C12-C13-O-C1' and O-C1'-C2'-C3', 45 
respectively, accordingly to reference 11b). 
Table 1. Computed MM-PBSA Binding Energies for the Most Favored 
Pose and Average Geometrical Parameters for the Bounded Taxanes.a  
 1 2 3 4 
ΔEMM-PBSA -39.7±7.0 -36.0±5.4 -36.6±5.4 -29.2±4.1 
d1 3.9±0.2 3.9±0.3 3.8±0.2 3.5±0.3 
d2 3.4±0.2 4.5±0.4 4.5±0.4 4.1±0.4 
d3 3.8±0.3 3.8±0.5 3.8±0.4 3.6±0.4 
d4 4.0±0.2 4.2±0.3 4.3±0.3 3.9±0.2 
φ1 76.8±5.8 85.7±9.7 94.2±8.9 61.7±12.2 
φ2 -56.9±7.4 -70.5±13.5 -59.7±9.2 -85.8±14.9 
φ3 -117.5±18.2 -112.3±23.8 -114.0±16.9 -139.7±23.1 
φ4 82.0±14.1 94.7±19.0 92.3±15.4 95.5±14.8 
a Geometrical parameters averaged upon frames sampled in the final ns 
trajectory of production run 50 
 As expected, the T-taxol conformation provided for 1 the best 
results in terms of both complex stability and ligand binding 
energy (Table S1, Paclitaxel(1) t-taxol). The same was observed 
for 3, where calculations starting from the pseudo-T-taxol 
conformation provided the lowest energies in terms of stability 55 
and binding energy (Table S1, IDN5839(3) pseudo-T-taxol). Less 
clean results were obtained for compounds 2 and 4, where three 
low energy complexes were obtained for the former (IDN5109(2) 
2_1, 2_2 and pseudo-T-taxol), and two for the latter (IDN5798(4) 
5_2 and pseudo-T-taxol). However, the pseudo-T-taxol 60 
conformation resulted in both cases the most favoured in terms of 
binding energies, confirming that 1 and the 1,14-heterofused 
taxanes 2-4 adopt similar binding modes.  
 The analysis of geometrical parameters (Figure 5 and Table 1) 
showed that d1, d3 and d4 distances are quite conserved, while d2 65 
distance is evidently longer for 1,14-heterofused taxanes, 
probably due to the substitution at C14. Concerning selected 
torsions, describing the side-chain orientation relatively to the 
main scaffold, a slight widening of φ1 and φ4 dihedrals is 
observed for compounds 2 and 3 with respect to 1, while only the 70 
former shows a widening of φ2 of about 10 deg. A different 
behaviour is observed for compound 4, which presents a narrower 
φ1 (61.7±12.2 deg.) and wider φ2 and φ3 (-85.8±14.9 and -
139.7±23.1, respectively). This behaviour might be due to the 
strong H-bond that can be formed between the side-chain tert-75 
butyloxycarbonyl and the cyclic NH at C14, which characterizes 
compound 4. 
 The analysis of intermolecular H-bonds between β-tubulin and 
taxanes 1-4 (Table 2) shows interactions with Asp 26’, Thr 274’ 
and Arg 282’ for all of them. 1 also shows a rather persistent H-80 
bond with Gln 280’ and Gly 360’, while the neighbouring Arg 
359’ establishes a quite stable and peculiar H-bond with 3. 
Similarly to 1, 2 also establishes H-bonds with Gln 280’ and Gly  
360’, even if their average occupancy is lower, while no H-bonds 
are observed for compound 4 with Gln 280’, Arg 359’ or Gly 85 
360’. It should be noted that an H-bond, even if showing a low 
average occupancy (8.2%), was also detected between the 
compound 3 carbonyl of the 1,14 ring and His 227’. 
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Table 2. H-bond analysis.a H-bonds with an average occupancy above 
40% for at least one compound are reported 
 average occupancy (%) 
H-Bonds 1 2 3 4 
Asp26’-COO∙∙∙HN-C3’ 93.6 93.3 89.5 57.6 
Asp26’-COO∙∙∙HO-C2’ 99.9 92.0 79.6 n.d. 
Thr274’-NH∙∙∙O-C10 96.1 88.5 65.1 26.0 
Gln280’-NH2∙∙∙O=C6 93.8 9.5 n.d. n.d. 
Arg282’-NH2∙∙∙O-C8 17.8 n.d. 58.2 6.5 
Arg282’-NH2∙∙∙O=C6 n.d. n.d. n.d. 46.4 
Arg282’-NH2∙∙∙OC(CH3)O-C5 59.6 25.0 17.2 n.d. 
Arg359’-NH∙∙∙O-C2’ n.d. n.d. 66.9 n.d. 
Gly360’-NH∙∙∙O-C2’ 88.1 28.3 n.d. n.d. 
a Parameters for H-bond analysis: donor-acceptor distance: 3.5 Å; donor-
H-acceptor angle 120.0 deg. The analysis was performed on the last ns of 
the production run trajectory. 5 
 MM-PBSA binding energies are comparable for all the 
investigated compounds, in line with previously reported results 
on cytotoxic activity (IC50 on MCF7 tumor cell lines for 1,
18 and 
2, 3, 419 are 1.7±0.40, 1.6±0.10, 0.4±0.10 and 1.0±0.04 nM, 
respectively), even if, in discordance with experiments, 10 
compound 4 resulted the less favoured.  
 Analysis of the effects of taxanes at the tubulin 1α-2β interface. 
Although we did not expect force field methods to discriminate 
ligands with such a narrow potency interval, the above 
computational result might conceal a behaviour that goes farther 15 
than the simple differences in binding affinity. For this reason, we 
decided to test the effects of 1-4 on the interaction energy 
between two consecutive tubulin dimers, a closer model of a 
tubulin protofilament structure. 
Table 3. MM-PBSA energy decomposition analysis for the protein-20 
protein interaction between tubulin 1α and 2β subunits evaluated from the 
MD of 1β,1α-2 β,2α tetramer;a single contributions (kcal/mol) for selected 
amino acids are reported relatively to unbounded tetramer.b Total MM-
PBSA binding energy (ΔEbinding, kcal/mol) for the 1α-2β dimer-dimer 
interaction is also reported.c 25 
  per residue ΔΔEbound-unbound (kcal/mol) 
Chain Residue 1 2 3 4 
1α Arg2 -0.4 0.0 -3.7 -5.6 
1α Lys163 -0.3 -0.2 -0.6 -4.2 
1α Glu254 -2.1 0.7 -0.2 -2.0 
1α Asp345 -1.1 -1.7 -0.3 -2.0 
1α Pro348 -2.3 -1.1 -1.1 -1.0 
1α Thr349 -0.8 2.0 0.1 -1.6 
2β Glu69’ 0.3 0.0 -0.1 -2.4 
2β Arg390’ 3.6 2.4 3.5 3.6 
2β Arg391’ 2.8 1.7 1.0 0.0 
2β Phe394’ -1.4 -2.4 -0.9 -3.2 
     
ΔEbinding -39.1±5.6 -33.6±8.4 -52.1±6.5 -72.1±6.8 
a The analysis was performed on the last ns of the production run 
trajectory. b Single residue contribution are computed as the difference 
between taxane bounded and unbounded tubulin. Only contributions 
where |ΔΔE| > 2 kcal/mol for at least one compound are reported. c The 
ΔEbinding computed for the unbounded tetramer is -39.1±8.0 kcal/mol. 30 
 MD simulations were performed on models of the 1β,1α-2β,2α 
tubulin tetramer, derived from the 3N2G tubulin tetramer crystal 
structure,20 unbounded or bounded with 1-4 in their most 
favoured binding poses (Figure S1). 
 The binding energy between the 1α-2β subunits was then 35 
computed and decomposed into single residue contributions by 
MM-PBSA analysis of the last ns of production run trajectory. 
Computed relative energies with respect to unbounded tubulin, 
are reported in Table 3, while the full set of energies is provided 
as Supporting Information (Table S2). 40 
 Unexpectedly, compound 4 provided the highest stabilization 
of the dimer-dimer interaction (MM-PBSA ΔEbinding=-72.1±6.8 
kcal/mol), followed by 3 which also provided a significant 
stabilization with respect to the unbounded tubulin (ΔEbinding=-
52.1±6.5 and -39.1±8.0 kcal/mol, respectively). On the other 45 
hand, neither compound 2 nor 1 significantly affected the 1α-2β 
interaction energy. These data suggest that the principal 
microtubule stabilizing action of compounds 1 and 2 might occur 
by improving the parallel interaction between adjacent 
protofilaments, as suggested by Mitra and co-workers,13 while an 50 
additional stabilization mechanism, exerted by improving the 
head-tail dimer-dimer affinity, could be expected for compounds 
3 and 4. 
Experimental Study. 
 In order to assess the interaction of compounds 1-4 with the 55 
tubulin/microtubule system, they were initially tested in an in 
vitro tubulin polymerization assay at fixed concentration of 10 
μM. As shown by the kinetics of assembly reported in Figure 6A, 
compounds 1-4 induce tubulin polymerization even in the 
absence of GTP.  60 
 
Figure 6. (A) Tubulin assembly was recorded as a function of time by 
measuring the increase in absorbance at 350 nm. Tubulin (13 μM) was 
polymerised in assembly buffer without GTP in the presence of 
compounds 1-4 at 10 μM concentrations. (B) Nucleation phase was 65 
analysed by extrapolating the parameter p from assembly kinetics, as 
shown in the inset, obtained in the presence of 1 or compounds 3, 4. (C) 
DIC microscopy images of microtubules assembled in the presence of 
compounds 1-4 (Bar, 2 μm). 
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Figure 7. Microtubule organization in human MCF7 cells exposed for 1 
and 72 h to compounds 1 (1.7 nM), 2 (1.6 nM), 3 (0.4 nM), and 4 (1 nM), 
as revealed by immunofluorescence localization of α-tubulin (red). Nuclei 
are stained by DAPI (blue). Scale bars, 20 μm 5 
 However, as the kinetics appear not to be perfectly superposed 
in the presence of the different compounds, we carried out further 
analyses to calculate a range of parameters characteristic of the 
assembly kinetics: nucleation, elongation, and steady state phase. 
From nucleation phase we extrapolated the parameter p (see 10 
Experimental Section) and found that it was significantly reduced 
by the compounds 3 and 4 with respect to 1 (Figure 6B), 
suggesting these compounds as more effective than 1 in 
favouring microtubule nucleation. 
Table 4. Kinetic parameters of tubulin assembly in the presence of 15 
compounds 1-4 (10 μM). 
cmpd Vi ± sem ΔA ± sem 
1 0.074±0.029 0.220±0.052 
2 0.081±0.026 0.188±0.018 
3 0.159±0.040* 0.235±0.045 
4 0.158±0.027* 0.285±0.031 
* p<0.05 vs 1 according to ANOVA, Tukey post hoc. 
 Table 4 reports the maximal velocity of polymerization (Vi) 
and the steady state extent of assembly (ΔA) extrapolated by the 
assembly kinetics shown in Figure 6A. Compounds 3 and 4 20 
induce a significant increase in Vi with respect to 1 showing the 
ability to improve the elongation phase as well as observed above 
for nucleation. Conversely, the steady state extent of assembly is 
comparable in the presence of 1 and all the tested compounds. 
Looking at microtubule morphology, we collected the assembled 25 
microtubules at the end of polymerization and analysed them by 
DIC microscopy (Figure 6C). Our results show that microtubules 
assembled in the presence of 1 and its derivatives show a similar 
morphology. 
 Finally, to investigate the effects of the compounds on 30 
microtubule organization in cells and, possibly, correlate these 
effects with their anti-proliferative activity, we have exposed 
MCF7 cells to 1-4 for 1 and 72 hours at concentrations 
corresponding to their IC50.
18,19 At the end of the treatment, cells 
were fixed, microtubules stained with anti-α-tubulin antibodies 35 
and observed by fluorescence microscopy (Figure 7).  
 In control cells, we observed a widespread network of long 
microtubules other than the typical accumulation of microtubules 
at one side of the nucleus called the microtubule organizing 
centre (MTOC). Compound 1 induces the typical accumulation of 40 
microtubules in bundles at both 1 and 72 h of incubation times 
and a similar effect is evoked by 2. On the contrary, compounds 3 
and 4 appear to induce a more dramatic reorganization of the 
microtubules at early time points: cells appear roundish after 1 h 
of incubation with the above compounds and few bundles are 45 
detectable. To conclude, our in vitro results highlight that 
chemical modifications in derivatives 3 and 4 potentiate the well-
known taxol ability to influence tubulin assembly kinetics by 
improving nucleation and elongation. In addition, these 
compounds evoked more severe effects on microtubule 50 
organization in MCF7 cells, in perfect agreement with our 
findings from the above reported computational study. 
Conclusions. 
The unbounded and bounded conformations of some biologically 
active 1,14-heterofused taxanes were investigated by MD 55 
simulations and results were compared to the known postulated 
bioactive conformation of paclitaxel. We evidenced that 
compounds 2-4 present unbounded geometries comparable to the 
T-taxol model and these conformations, herein referred as 
pseudo-T-Taxol, also resulted the most stable for the bounded 60 
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taxanes. Interestingly, although the amido-derivative 4 showed 
some deviation from the pseudo-T-taxol conformation and also 
the lowest computed binding affinity, it provided the highest 
stabilization of the α1-β2 interaction in a tubulin tetramer model, 
followed by compound 3. 5 
The different behaviour of 3 and 4 with respect to ortataxel 2, 
also characterized by a 1,14-carbonyl bridge, might depends on 
the different physical-chemical features of the substituent at C14. 
Indeed, in compound 4 a strong hydrogen bond is formed 
between the carbamic nitrogen and the carboxy group of BOC in 10 
the side-chain. In 2 such an attractive interaction is replaced by a 
repulsion between the same group and the oxygen of the 
carbonate. Compound 3 lies in the middle between 2 and 4, 
providing that the substitution of position 14 with methylidene 
does not cause a repulsive or an attractive interaction. 15 
Biological data consolidate the computational outcomes and 
highlight the significant impact of the 1,14-heterofused taxanes 3 
and 4 on tubulin kinetics and organization. As 3 and 4 speed up in 
vitro tubulin assembly by promoting the nucleation phase, these 
derivatives likely attest an improved ability to stabilize 20 
microtubules. Next, compounds 3 and 4 affect microtubule 
network in cell earlier than paclitaxel 1. Although we cannot 
exclude that the precocious microtubule collapse observed in 
cells exposed to compounds 3 and 4 could be amplified by 
additional and not-microtubule dependant mechanisms, our data 25 
clearly show that chemical modifications in these derivatives 
augment paclitaxel performance in targeting tubulin organization 
in cell and, consequently, in inhibiting cell growth. 
Experimental Section 
Computational Methods. Conformational searches for 1-4 were 30 
done using low-mode molecular dynamics with the MMFF94x 
force field and Born solvation, as implemented in the MOE 
software.16 The α,β-tubulin structure was obtained from the 1JFF 
crystal structure15 by reconstructing missing residues through the 
homology model module implemented in MOE. The model was 35 
then protonated with the H++ server accordingly to a pH of 6.5 
and a salinity of 0.15 M,21 and then relaxed by a force field 
minimization (Amber force field implemented in MOE) with 
backbone restraints (tether atom = 1000). Docking were 
performed with MOE and two protocols well reproduced the 40 
paclitaxel binding conformation as found in 1JFF. Protocol 1, 
using the Triangle Matcher algorithm with default settings and 
London dG scoring function, followed by force field refinement 
(MMFF94x) of the poses and rescoring (London dG), provided 
the best matching with the T-taxol conformation for the first pose 45 
(r.m.s.d. = 0.81 Å). Protocol 2, using the Alpha Triangle 
algorithm (800000 and 5000000 for minimum and maximum 
iteration, respectively, timeout = 6000 seconds) and Affinity 
scoring function, followed by force field refinement and 
rescoring (Affinity), provided an r.m.s.d. = 1.83 Å for the first 50 
pose, but 0.81 and 1.00 Å for the second and third, respectively. 
Both protocols were chosen, the first because it produced the best 
fitting for the top-ranked pose, the second because it was able to 
find the highest number of low r.m.s.d. geometries within the top-
five poses. The top-five poses of compounds 1-4 were then used 55 
to generate α,β-tubulin complexes for MD simulations. Analogue 
complexes were also prepared using the lowest energy 
conformation obtained by the previously described 
conformational search. All complexes were neutralized by adding 
19 Na+ ions and solvated by a cubic TIP3P water box extending 60 
up to 10 Å from the solute. Orientation and conformation 
independent RESP charges were derived for ligands 1-4 using the 
REDIII procedure on two conformations and two orientations,22 
using the Gaussian03 software for ab-initio geometry 
optimization and molecular electrostatic potential calculation.23 65 
Parameters for GTP and GDP residues were downloaded from 
the Amber parameter database.24 MD simulations were performed 
with the pmemd module of the Amber11 program package using 
the ff03 and gaff force fields.25,26 All complexes were minimized, 
heated up to the final temperature of 300 K by six consecutive 50 70 
ps runs in which backbone restraints were gradually released 
from 10 to 5 kcal/mol•Å and ligands restraints released from 5 to 
0.5 kcal/mol•Å. These restraints were also kept for the following 
100 ps equilibration in NVT ensemble and 100 ps in NPT 
ensemble, then were gradually reduced to 0 during the following 75 
400 ps of NPT equilibration. A 2 ns production run was then 
conduced on the unrestrained systems. A cut-off for electrostatic 
of 8 Å, a time step of 0.002 ps and the SHAKE algorithm, 
constraining bonds involving hydrogens, were applied to all 
calculation.27 The same protocol, extended to 4 ns of production 80 
run, was applied for the MD simulation of the 1β,1α-2β,2α 
tubulin tetramer (unbounded or bounded with 1-4), obtained by 
superposing two units of the previously described dimers to the 
tubulin tetramer crystal structure 3N2G,20 in order to preserve the 
taxol binding site. Geometrical analyses and MM-PBSA 85 
calculations (50 snapshots at regular intervals) were performed in 
all cases on the last ns of the production run. Both Generalized 
Born and Poisson Boltzmann methods were applied for 
evaluating the electrostatic contribution to solvation energy, 
obtaining comparable results (Table S1, Supporting Information). 90 
MD trajectory analyses were performed with both ptraj and VMD 
1.8.5.28 
Tubulin assembly assay. Tubulin was purified from bovine 
brain purchased from a local slaughterhouse, conserved before 
use in ice-cold PBS (20 mM Na-phosphate, 150 mM NaCl, pH 95 
7.2) and used as soon as possible. Pure tubulin was obtained by 
two cycles of polymerization-depolymerization in a high-molarity 
buffer,29 resuspended in BRB80 (80 mM K-Pipes pH 6.9, 2 mM 
EGTA, 1 mM MgCl2), snap-frozen in aliquots in liquid nitrogen 
and kept at -80°C. Protein concentration was determined by 100 
MicroBCA assay kit (Pierce). Stock solutions of the drugs were 
prepared by dissolving the powers at a concentration of 5 mM in 
methanol. To assess their effects on tubulin assembly, bovine 
tubulin (1.3 mg/ml) was mixed with different compounds or an 
equal volume of the solvent (final 1% methanol) in an assembly 105 
buffer minus GTP (80 mM K-Pipes pH 6.9, 2 mM EGTA, 1 mM 
MgCl2, 10% glycerol). The reaction mixtures (55 μl) were 
prepared at 0 °C, and each reaction was started by plating the 
cuvette at 37 °C in an Ultraspec 300 spectrophotometer 
(Pharmacia) equipped with a temperature controller. The kinetics 110 
of tubulin polymerisation were assessed by turbidimetry analysis 
following the increase in absorbance at 350 nm for 30 min. At 
least three independent experiments were performed with each 
compound.  
Kinetic parameters of tubulin assembly. The reaction of 115 
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tubulin assembly has been analyzed to point out the potential 
effects of the selected compounds on the kinetic parameters 
defining its different phases: nucleation, elongation and steady 
state. Nucleation is a lag phase, during which a stable nucleus is 
forming, and allows microtubule polymerization. From 5 
nucleation phase we extrapolated the parameter p that represents 
the number of successive steps in the nucleation process by 
plotting log(A(t)/A∞) against log t.
30 Elongation develops after 
the lag phase and is the phase during which the maximum extent 
of tubulin polymerization occurs following a procedure that is 10 
strongly similar to a first order chemical reaction.31 At very initial 
elongation phase, one can extrapolate the maximal velocity of 
polymerization (Vi), as the variation of mass during time (dA/dt). 
Finally, steady state is the terminal phase during which the total 
amount of microtubules does not change because the rates of 15 
microtubule growth and shortening are identical. We extrapolate 
the steady state extent of assembly (ΔA) as the absorbance 
maximum obtained at the plateau of the kinetics curve minus the 
absorbance measured at the initial elongation phase.  
Differences between the effects of the different compounds on p 20 
value, Vi and ΔA were evaluated by ANOVA followed by 
Dunnett post hoc test.  
DIC microscopy. At the end of the assembly assay, microtubules 
were collected by centrifugation at 30,000g for 30 min at 30 °C, 
fixed with 0.5% glutaraldehyde in the assembly buffer (80 mM 25 
K-Pipes pH 6.9, 2 mM EGTA, 1 mM MgCl2, 10% glycerol), and 
put onto coverslips. Image acquisition was performed using a 
Zeiss Axiovert 200 equipped with differential interference 
contrast (DIC) optics, a 63× oil objective, and a digital image 
recording system (Axiocam HRM Rev. 2 camera driven by 30 
Axiovision software rel. 4.4, Zeiss). 
Cell culture and immunofluorescence analyses. Microtubule 
organization in cell was revealed by indirect immunofluorescence 
(IF) analyses. Human breast adenocarcinoma cell line MCF7 
(HTB-22; American Type Culture Collection, Rockville, MD, 35 
U.S.A.) was grown in minimal essential medium with Earle’s (E-
MEM), supplemented with 10% fetal bovine serum (Hyclone 
Europe, Oud-Beijerland, Holland), 2 mM L-glutamine, 100 U/ml 
penicillin and non-essential amino acids. Cells were maintained 
at 37 °C in a humidified atmosphere at 5% CO2. Experiments 40 
were carried out with cells plated on glass coverslips at a density 
of 1.0  104 cells/cm2 and grown for 24 h in control medium 
following an incubation of 1h and 72 h in the presence of the 
drugs (final concentration corresponding to the IC50 previously 
determined by proliferation assay)18,19 or solvent vehicle alone 45 
(methanol) diluited 1:1000 in the culture medium. At the end of 
the treatments, cells were fixed and stained as previously 
described.32 Briefly, MCF7 cells were fixed and permeabilized 
for 6 min with methanol at –20 °C, washed with PBS and blocked 
in PBS + 5% bovine serum albumin (BSA) for 15 min at room 50 
temperature. To localize tubulin, the cells were incubated with 
monoclonal anti α-tubulin antibody (clone B-5-1-2, Sigma-
Aldrich), 1:500 in PBS for 1 h at 37 °C. As secondary antibodies 
we used goat anti-mouse Alexa FluorTM 568 (Molecular Probes), 
1:1000 in PBS + 1% BSA for 45 min at 37 °C. Nuclei staining 55 
was performed by incubation with DAPI (0.25 μg/ml in PBS) for 
15 min at room temperature. The coverslips were mounted in 
Mowiol (Calbiochem)–DABCO (Sigma-Aldrich) and examined 
with a Zeiss Axiovert 200 microscope equipped with a 63 
Neofluor lens. Images were acquired with an Axiocam camera 60 
(Zeiss) and PC running Axiovision software (Zeiss). 
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